DNLI Denali Therapeutics Inc

Price (delayed)

$20.15

Market cap

$3.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.88

Enterprise value

$3.04B

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 65
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 7

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing ...

Highlights
The EPS has decreased by 7% YoY but it has increased by 3% from the previous quarter
Denali Therapeutics's equity has decreased by 18% YoY and by 9% QoQ
The net income is down by 12% year-on-year

Key stats

What are the main financial stats of DNLI

DNLI stock price

How has the Denali Therapeutics stock price performed over time
Intraday
2.49%
1 week
-3.82%
1 month
7.93%
1 year
39.74%
YTD
22.05%
QTD
4.95%

Financial performance

How have Denali Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$547.12M
Net income
-$508.02M
Gross margin
N/A
Net margin
N/A
The net income is down by 12% year-on-year
DNLI's operating income is down by 6% year-on-year

Price vs fundamentals

How does DNLI's price correlate with its fundamentals

Growth

What is Denali Therapeutics's growth rate over time

Valuation

What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
3.45
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 7% YoY but it has increased by 3% from the previous quarter
DNLI's price to book (P/B) is 35% more than its last 4 quarters average of 2.5 but 3.7% less than its 5-year quarterly average of 3.5
Denali Therapeutics's equity has decreased by 18% YoY and by 9% QoQ

Efficiency

How efficient is Denali Therapeutics business performance
The return on invested capital has dropped by 51% year-on-year and by 4.6% since the previous quarter
The return on equity has declined by 45% year-on-year and by 4.2% since the previous quarter
The return on assets has declined by 35% year-on-year

Dividends

What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNLI.

Financial health

How did Denali Therapeutics financials performed over time
DNLI's total liabilities has surged by 159% since the previous quarter and by 129% year-on-year
The company's total assets rose by 11% QoQ
Denali Therapeutics's debt is 75% less than its equity
Denali Therapeutics's equity has decreased by 18% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.